Bridge
GLP compliant drug development in the US & China
Home
About Us
Services
US Services
General Toxicology
Safety Pharmacology
DART
Vaccines
China Services
Toxicology
Immunology
Bioanalytical Chemistry/DMPK
Vaccines
News
Articles
Press Releases
Meetings
Careers
Contact Us
Press Releases
MEDIA CONTACT:
Vincent Lagrotteria, MBA
240-364-6300
info@bridgelaboratories.com
www.bridgelaboratories.com
2008 Releases
October
07
Bridge Laboratories Awarded Major Contract to Support the National Institute on Drug Abuse (NIDA)
September
02
Bridge Laboratories announced today that data from its China lab has been accepted by the FDA.
July
29
Bridge Laboratories Reaches Agreement to Build 2nd Facility in Beijing
January
14
Bridge Laboratories Receives $18 million Financial Backing
2007 Releases
December
15
Bridge Acquires US-based Preclinical Study Company
August
6
Bridge Laboratories' China Facility Receives Full AAALAC Accreditation: First Preclinical CRO with US and China Multispecies Capabilities
February
14
Bridge Announces Closing of its $35 Million Series B Capital Raise to Accelerate its China and US ‘Hybrid’ CRO Model
February
1
Bridge Announces the CRO Industry’s First China-US Visiting Scholar Program for Its Employees
2006 Releases
October
6
Wan Yang Feng, Ph.D. has been appointed Director of Bioanalytic and Metabolism of Bridge Pharmaceutical's Preclinical Laboratory in Beijing
September
6
Bridge Successfully Validates Beijing Preclinical Laboratory
June
12
Bridge Announces $22 Million Series B Capital Raise
June
12
Patrik Sebastian Jeanmonod has been appointed Vice President Finance of Bridge Laboratories, Inc.
June
9
Bridge Laboratories Purchases Provantis Solution for New GLP Laboratory in China
2005 Releases
November
22
San Francisco Business Times: Bridging the biopharmaceutical gap with a new Chinese Lab
November
22
Bridge Laboratories Dedicates Its Preclinical Drug Development Laboratory in Beijing